Typical Weekly Pattern During This Phase Weight loss: 1-2 pounds weekly early in phase, gradually decreasing to 1-1.5 pounds weekly by week 24 Appetite: Strongly suppressed throughout
[unique_description_2]
A healthcare provider helps ensure: Appropriate patient selection based on BMI, medical history, and metabolic risk factors Safe dose escalation , reducing the likelihood of gastrointestinal side effects Monitoring for contraindications , including thyroid conditions or pancreatitis risk Assessment of treatment response , including weight trends and metabolic markers Long-term planning , as Wegovy is designed for chronic weight management rather than short-term use Without medical oversight, patients may misuse dosing schedules, discontinue treatment prematurely, or overlook side effects that require adjustment
COVID-19 patients exhibit reduced procoagulant platelet responses
Losing weight can reduce the risk of heart disease, improve mobility, and increase energy levels
reconstituted: refrigerate at 28 C (35.646.4 F) and use within 30 days
